基于网络药理学,探索使用芬瑞来保护心脏病的机制
Yachen Si1,2, Ying Zhu3, Jing Liu3
1Department of Internal Medicine, No. 944 Hospital of Joint Logistics Support Force, Jiuquan, China.
Cardiorenal medicine
|May 27, 2024
概括
菲内伦通过准多个分子通路,显示出心脏和脏的益处. 这项网络药理学研究揭示了其在治疗心脏病,特别是2型糖尿病 (T2DM) 方面的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 网络药理学 网络药理学
- 心血管和脏医学 心血管和脏医学
背景情况:
- 芬瑞能降低慢性病和2型糖尿病 (T2DM) 患者的心血管死亡和功能衰竭.
- 了解费内伦的分子机制对于优化心脏病治疗至关重要.
研究的目的:
- 通过使用网络药理学,探索菲内伦在治疗心脏病和脏病中的分子机制.
- 为了确定关键的目标和受 finerenone 影响的途径.
主要方法:
- 使用多个数据库 (STITH,瑞士目标预测等) 为了识别fineerenone目标和与疾病相关的基因.
- 构建了蛋白质-蛋白质相互作用 (PPI) 网络,并进行了基因本体学 (GO) 和基因和基因组 (KEGG) 京都百科全书路径丰富分析.
- 在糖尿病小鼠模型中,通过分子对接,组织病理学 (HE染色) 和西部涂抹验证了这些发现.
主要成果:
- 确定了111个潜在的心脏和脏的目标.
- 关键途径包括糖尿病并发症和糖尿病心肌病中的 AGE-RAGE 信号.
- 芬瑞诺在糖尿病小鼠中证明了心脏和脏的保护,逆转了改变的蛋白质表达 (CASP3,EGFR,ALB).
结论:
- 菲内伦通过一个多目标,多途径机制来发挥心脏和脏的益处.
- 这项研究提供了关于finerenone在心脏和脏疾病中的治疗效果的分子见解.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:25Antihypertensive Drugs: Direct Renin Inhibitors
597
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
597
01:11Renal Failure: Dose Adjustments
84
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
84
01:28Renal Drug Excretion: Tubular Secretion
175
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
175
01:17Factors Affecting Renal Clearance: Renal Impairment
86
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
86